鐵建裝備(01786.HK)2019年純利減21.87%至1.22億元
格隆匯3月20日丨鐵建裝備(01786.HK)公佈,2019年全年,實現收入21.09億元(人民幣,下同),同比減12.51%;母公司擁有人應占純利1.22億元,同比減21.87%;基本每股收益0.08元。
2019年,在董事會、管理團隊和全體員工的共同努力下,公司高質量發展開啟新篇章,改革發展和生產經營呈現新局面,公司努力確保企業經營穩中求進,難中有為。這一年,海外市場新籤合同額再創新高,佔新籤合同總額近三分一,海外市場經營取得新突破,成為公司發展新的增長點。
這一年,公司推出的新產品數量和種類均為歷年最,共有七個自主研發的新產品試製成功,科技研發取得重大成果,未來可期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.